Guangzhou, China-based commercial-stage biopharmaceutical firm Bio-Thera Solutions and Hyderabad-based Dr. Reddy’s Laboratories, through one of its subsidiaries, signed commercialisation and license agreements for BAT2206, a proposed biosimilar of Johnson & Johnson’s Stelara and BAT2506, which is a proposed biosimilar of J&J’s Simponi.
Under the agreement, Bio-Thera will be responsible for development, manufacturing and supply of BAT2206 and BAT2506. Dr. Reddy’s will be responsible for seeking regulatory approvals as well as commercialisation in the licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, Philippines, Thailand, Vietnam.
In addition, Dr. Reddy’s will also receive the exclusive commercial rights to BAT2206 in Colombia.
“This is our first partnership focused solely on Southeast Asia and Dr. Reddy’s is the perfect partner to help bring BAT2206 and BAT2506 to patients in the region”, Bio-Thera CEO Shengfeng Li said.
“Our partnership with Bio-Thera enables us to further expand our biosimilars offerings in the emerging markets,” Dr. Reddy’s CEO – Branded Markets (India and Emerging Markets) M.V. Ramana said.
In the European Union, Stelara is currently approved for treatment of moderate to severe plaque psoriasis in adults and children aged above 6 years; active psoriatic arthritis; moderately to severely active Crohn’s disease in adults; and moderately to severely active ulcerative colitis in adults.
Originator product Simponi is approved in the U.S. for moderate to severe rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis and moderate to severely active UC and carries a boxed warning for serious infection and malignancy, Dr. Reddy’s and Bio-Thera Solutions said in a release.
Published – March 26, 2025 09:26 pm IST
